EUR 2.85
(-2.9%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 99.73 Million CAD | -11.51% |
2022 | 112.71 Million CAD | 19.64% |
2021 | 94.21 Million CAD | 62.19% |
2020 | 58.08 Million CAD | 85.37% |
2019 | 31.33 Million CAD | 1101.96% |
2018 | 2.6 Million CAD | -87.45% |
2017 | 20.76 Million CAD | 2.35% |
2016 | 20.29 Million CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 92.25 Million CAD | 5.78% |
2024 Q1 | 87.21 Million CAD | -12.56% |
2024 Q3 | 90.81 Million CAD | -1.56% |
2023 Q3 | 102.87 Million CAD | -0.81% |
2023 Q1 | 110.09 Million CAD | -2.32% |
2023 Q2 | 103.71 Million CAD | -5.8% |
2023 FY | 99.73 Million CAD | -11.51% |
2023 Q4 | 99.73 Million CAD | -3.05% |
2022 FY | 112.71 Million CAD | 19.64% |
2022 Q4 | 112.71 Million CAD | 5.18% |
2022 Q3 | 107.15 Million CAD | -5.41% |
2022 Q2 | 113.29 Million CAD | 4.65% |
2022 Q1 | 108.25 Million CAD | 14.91% |
2021 Q2 | 93.52 Million CAD | -17.07% |
2021 Q4 | 94.21 Million CAD | 7.83% |
2021 Q3 | 87.37 Million CAD | -6.58% |
2021 FY | 94.21 Million CAD | 62.19% |
2021 Q1 | 112.77 Million CAD | 94.15% |
2020 Q1 | 58.61 Million CAD | 87.06% |
2020 Q4 | 58.08 Million CAD | -6.65% |
2020 Q2 | 65.18 Million CAD | 11.2% |
2020 Q3 | 62.22 Million CAD | -4.54% |
2020 FY | 58.08 Million CAD | 85.37% |
2019 FY | 31.33 Million CAD | 1101.96% |
2019 Q4 | 31.33 Million CAD | 18.45% |
2019 Q1 | 13.88 Million CAD | 432.72% |
2019 Q3 | 26.45 Million CAD | 12.66% |
2019 Q2 | 23.48 Million CAD | 69.09% |
2018 FY | 2.6 Million CAD | -87.45% |
2018 Q4 | 2.6 Million CAD | 1.57% |
2018 Q1 | - CAD | -100.0% |
2018 Q3 | 2.56 Million CAD | 0.0% |
2017 Q4 | 20.76 Million CAD | 0.0% |
2017 FY | 20.76 Million CAD | 2.35% |
2016 FY | 20.29 Million CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 55.8 Million EUR | -78.733% |
Redcare Pharmacy NV | 528.37 Million EUR | 81.124% |